Large cell differentiation of metastatic prostate cancer after androgen deprivation therapy

被引：1
|
作者：
Patel, Rutveej [1 ]
Faiena, Izak [1 ]
Geltzeiler, Jules [2 ]
机构：
[1] Rutgers Robert Wood Johnson Med Sch, Div Urol, New Brunswick, NJ USA
[2] Jersey Shore Univ, Med Ctr, Div Urol, Neptune, NJ USA
来源：
CANADIAN JOURNAL OF UROLOGY | 2015年 / 22卷 / 02期
关键词：
large cell neuroendocrine tumor; prostate cancer; hormone refractory prostate cancer; neuroendocrine differentiation; NEUROENDOCRINE DIFFERENTIATION;
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
We present a case of a 75-year-old male with a history of high risk prostate cancer who underwent androgen deprivation therapy and palliative radiation treatments for his disease. Subsequently, he presented with gross hematuria and severe lower urinary tract symptoms. A palliative transurethral resection of the prostate (TURP) at that time, demonstrated large cell differentiated neuroendocrine carcinoma with metastasis to the lung. We review the limited literature on this rare form of disease and present current treatment strategies.
引用
收藏
页码：7752 / 7754
页数：3
相关论文
共 50 条
  • [11] Androgen deprivation therapy for prostate cancer
    Das, Manjulika
    LANCET ONCOLOGY, 2017, 18 (10): : E567 - E567
  • [12] Androgen deprivation therapy for prostate cancer
    Sharifi, N
    Gulley, JL
    Dahut, WL
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2005, 294 (02): : 238 - 244
  • [13] Androgen deprivation therapy for prostate cancer
    Bahnson, Robert
    JOURNAL OF UROLOGY, 2007, 178 (04): : 1148 - 1148
  • [14] Androgen deprivation therapy for prostate cancer
    Singer, Eric A.
    Golijanin, Dragan J.
    Miyamoto, Hiroshi
    Messing, Edward M.
    EXPERT OPINION ON PHARMACOTHERAPY, 2008, 9 (02) : 211 - 228
  • [15] Re: Use of Androgen Deprivation Therapy for Metastatic Prostate Cancer in Older Men
    Daneshmand, Siamak
    EUROPEAN UROLOGY, 2008, 54 (05) : 1201 - 1202
  • [16] Trends and Racial Differences in the Use of Androgen Deprivation Therapy for Metastatic Prostate Cancer
    Carson, April P.
    Howard, Daniel L.
    Carpenter, William R.
    Taylor, Yhenneko J.
    Peacock, Sharon
    Schenck, Anna P.
    Godley, Paul A.
    JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2010, 39 (05) : 872 - 881
  • [17] Continuous vs. intermittent androgen deprivation therapy for metastatic prostate cancer
    Langenhuijsen, Johan F.
    Badhauser, Dirk
    Schaaf, Berthold
    Kiemeney, Lambertus A. L. M.
    Witjes, J. Alfred
    Mulders, Peter F. A.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2013, 31 (05) : 549 - 556
  • [18] Effect of Neoadjuvant Intense Androgen Deprivation Therapy in Neuroendocrine Differentiation of Prostate Cancer
    Montaser, Laleh
    Calagua, Carla
    Schaefer, Rachel
    Lis, Rosina
    Zhang, Zhenwei
    Loda, Massimo
    Taplin, Mary-Ellen
    Balk, Steven P.
    Ye, Huihui
    LABORATORY INVESTIGATION, 2017, 97 : 244A - 244A
  • [19] Neuroendocrine differentiation in hormone refractory prostate cancer following androgen deprivation therapy
    Hirano, D
    Okada, Y
    Minei, S
    Takimoto, Y
    Nemoto, N
    EUROPEAN UROLOGY, 2004, 45 (05) : 586 - 592
  • [20] Effect of Neoadjuvant Intense Androgen Deprivation Therapy in Neuroendocrine Differentiation of Prostate Cancer
    Montaser, Laleh
    Calagua, Carla
    Schaefer, Rachel
    Lis, Rosina
    Zhang, Zhenwei
    Loda, Massimo
    Taplin, Mary-Ellen
    Balk, Steven P.
    Ye, Huihui
    MODERN PATHOLOGY, 2017, 30 : 244A - 244A
12345